Mounjaro label adds KwikPen never-share warning and device retraining rule

Eli Lilly's January 2026 revision of the Mounjaro (tirzepatide) prescribing information adds a new warning section, 5.10, titled "Never Share a MOUNJARO KwikPen Between Patients," and expands section 2.2 with an instruction that patients and caregivers must be retrained and told to read the Instructions for Use for the new device when the prescribed presentation changes. The Zepbound label, the other tirzepatide product from Eli Lilly, records the identical section number and the same January 2026 date ^[2].

What the labels say

Zepbound's section 5.10 reads: "Never share a ZEPBOUND KwikPen between patients, even if the pen needle is changed" ^[2]. Ozempic (semaglutide) has carried a comparable warning for longer: section 5.4, "Never Share an OZEMPIC Pen Between Patients," with the same qualifier that changing the needle does not make sharing safe ^[1].

Four devices, one molecule

Zepbound's dosage forms and strengths section lists single-dose pens and single-dose vials in six strengths — 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg and 15 mg per 0.5 mL — plus multi-dose vials or single-patient-use KwikPens in the same six strengths, each KwikPen holding four 0.6 mL doses ^[2]. That adds up to four physically different delivery systems for one drug. Ozempic also ships in two formats: single-patient-use pens that hold four doses, and single-dose prefilled syringes of 0.25 mg, 0.5 mg or 1 mg per 0.5 mL ^[1].

The retraining language matters because the devices do not work the same way. A single-dose pen is discarded after one injection; a KwikPen holds four doses and has to be counted and stored between them ^[2]. Labeling that covers several presentations directs readers to the full prescribing information for the administration instructions attached to each one ^[2].

Who performs the retraining — the prescriber, the pharmacy or a caregiver — is not specified in the sections described. The exact wording of the expanded Mounjaro section 2.2, and the date it takes effect in pharmacies, have not been disclosed.

Why it matters for patients

Sharing an injection device can pass bloodborne infections, which is why both labels place "even if the needle is changed" directly in the warning ^[1][2]. The Mounjaro revision makes that instruction explicit for the KwikPen by name.

A change of device is not a cosmetic change. Moving from a single-dose pen to a four-dose KwikPen, or the reverse, changes how many times a device is used, how doses are counted and how the device is stored ^[2]. Putting retraining in section 2.2 means a switch in presentation is supposed to prompt fresh instructions rather than an assumption that a patient already knows the new device.

Patients who are handed a different device than before can expect separate written instructions. The labels do not say how quickly a prescriber or pharmacy must deliver them, and whether retraining is documented anywhere is not addressed in the sections described.

What happens next

The Zepbound label is dated 8/2026 and lists other recent changes: dosage and administration (2.4) in 01/2026, severe gastrointestinal adverse reactions (5.2) in 02/2026, removal of the suicidal behavior and ideation warning in 02/2026, and diabetic retinopathy complications in patients with type 2 diabetes (5.8) in 08/2026 ^[2]. The Ozempic label was most recently revised 05/2026, with severe gastrointestinal adverse reactions (5.7) dated 10/2025 ^[1]. Whether the Mounjaro label will receive further updates alongside those, or whether other GLP-1 labels will add matching retraining language, has not been disclosed.